According to a preliminary report posted on December 19 by the COG-UK Consortium scientists, as of December 15, 1,623 variant genomes have been sequenced. In a December 21 tweet, COG-UK Consortium said that it added 2,963 more genome sequences of SARS-CoV-2, of which 942 (32%) belong to the new variant. The Consortium intends to sequence 20,000 more SARS-CoV-2 genomes in the next two weeks to further ascertain the spread of the variant.

There is no clear proof, at least not yet, that it does cause severe pandemic. But there is a justification for seriously taking the possibility. Another coronavirus lineage in South Africa has acquired one specific mutation that is also present in B.1.1.7. This variant is increasingly spreading across South Africa's coastal regions. And doctors have observed in preliminary research that individuals infected with this variant bear a higher viral load-a higher concentration of the virus in their upper respiratory tract. In many viral diseases, this is associated with more severe symptoms.

DBT-Junior Research Fellowship (DBT-JRF) in Biotechnology (2020)

BIOTECHNOLOGY ELIGIBILITY TEST (BET) 2020

Applications are invited from bonafide Indian citizens, residing in India for award of “DBT-Junior Research Fellowship” (DBT-JRF) for pursuing research in frontier areas of Biotechnology and Life Sciences. The candidates will be selected through “Biotechnology Eligibility Test (BET)”. Based on the performance in BET, two categories of merit list will be prepared (Category-I and Category-II). Government of India norms for reservation will be followed for selection. Candidates selected under category-I will be eligible to avail fellowship under the programme. These will be tenable at any University/Institute in India where the selected candidate registers for PhD Programme. Candidates selected under Category-II will be eligible to be appointed in any DBT sponsored project and avail fellowship from the project equivalent to NET/GATE, subject to selection through institutional selection process. There will be no binding on Principal Investigators of DBT sponsored projects to select JRF for their project from category-II list. Selection in category-II will not entitle student for any fellowship from DBT-JRF programme.

ELIGIBILITY

Qualification: M.Sc./ M.Tech./ M.V.Sc. or equivalent degree/ Integrated BS-MS/ B.E./ B.Tech. in any discipline of Biotechnology, M.Sc./ M.Tech. Bioinformatics/ Computational Biology, students admitted under DBT supported Postgraduate Teaching Programs. M.Sc. Life Science/ Bioscience/ Zoology/ Botany/ Microbiology/ Biochemistry/ Biophysics and Masters in Allied areas of Biology/Life Sciences. Candidates appearing in the final year examination are also eligible to apply.

Marks: Minimum 60% marks for General, EWS & OBC category and 55% for SC/ ST/ Differently abled in aggregate (or equivalent grade).

Age Limit: Upto 28 years as on the last date of application for General & EWS category. Age relaxation of up to 5 years (33 years) for SC/ ST/ Differently Abled/ women candidates and upto 3 years (31 years) for OBC (Non-Creamy Layer) candidates.

For detailed procedure for filling the application form, payment of application fee and uploading of required documents/ certificates in the prescribed format, please visit: http://rcb.res.in/BET2020. A non-refundable and non-transferable application fee of Rs. 1000/-is payable online by General/ OBC/ EWS candidates and Rs 250/- by SC/ ST/ Differently abled candidates.

IMPORTANT DATES

During the first phase of ENCODE, published in 2007, microarray-based technologies were used to detect regions associated with transcription factors, certain histone modifications and open chromatin within a pre-specified 1% of the human genome.

ENCODE’s second phase saw a switch to sequencing-based technologies, the addition of new assay types and the analysis of functional elements genome-wide, described in a collection of research articles in 2012.

The Encyclopedia paper of ENCODE 3, published in Nature, gives an overview of the various assays that were performed in human and mouse cell lines and tissues and describes a Registry of human and mouse candidate cis-regulatory elements (cCREs).

More at https://www.nature.com/immersive/d42859-020-00027-2/index.html

Like other indel callers, Scalpel works by performing de novo assembly of regions of interest, so that misalignment to the reference genome cannot obscure the presence of an insertion or deletion. Scalpel's innovation is to repeatedly check its assembly before comparing to the reference genome, to account for simple sequence repeats that are a regular source of error in indel calling. When Scalpel assembles an exon, it collects reads that map to that exon (including partial matches), splits them into k-mers, and creates a de Bruijn graph to span the exon; however, if it detects repeats in the map, it iteratively increases the size of the k-mers by one base until the repeats are eliminated. This ensures that the final assembly of the exon is highly accurate while minimizing compute time.

The Cold Spring Harbor team's validation of Scalpel, published over the weekend in Nature Methods, compares Scalpel's performance on a live whole exome against HaplotypeCaller and SOAPindel. The donor is an individual with serious neurological disorders, which may be linked to a high incidence of indels. One thousand indels from this individual's exome, called by one or more of the informatics pipelines, were selected for focused resequencing. This resequencing revealed a 77% true positive rate for Scalpel calls, dramatically better than the rates for either of the competing tools; Scalpel performed especially well with indels longer than five base pairs, a traditional weak point for indel callers.

Finally, the authors demonstrate Scalpel's use on a large set of genetic data from nearly 600 families who donated samples to the Simons Simplex Collection, a project of the Simons Foundation Autism Research Initiative. Scalpel found a very high enrichment for indels in children affected by autism, compared with their unaffected siblings, a pattern that persisted even after excluding common variants.

The US born Sangeeta Bhatia at Massachusetts Institute of Technology (MIT) has developed a cheap, simple, paper test that can detect cancer. These diagnostic, which works much like a pregnancy test, could reveal within minutes, based on a urine sample, whether a person have cancer or not. The MIT media announce the major and amazing breakthrough in cancer diagonistics. These newly developed technology will allow non-communicable diseases to be detect at early stage, which will be cheap and easily accessible to the masses. For the developing world it would be exciting to adapt it instead to a paper test that could be performed on unprocessed samples in a rural setting, without the need for any specialized equipment. The simple readout could even be transmitted to a remote caregiver by a picture on a mobile phone.

The MIT professor and Howard Hughes Medical Institute investigator Sangeeta Bhatia, who is also the John and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, invented a new class of synthetic biomarker, which is highly specialized instrument to do these kind of analysis. These paper test essentially relies on nanoparticles that interact with tumor proteins called proteases, each of which can trigger release of hundreds of biomarkers that are then easily detectable in a patient's urine. The MIT nanoparticles are coated with peptides (short protein fragments) targeted by different MMPs. These particles congregate at tumor sites, where MMPs cleave hundreds of peptides, which accumulate in the kidneys and are excreted in the urine.

To create the test strips, the researchers first coated nitrocellulose paper with antibodies that can capture the peptides. Once the peptides are captured, they flow along the strip and are exposed to several invisible test lines made of other antibodies specific to different tags attached to the peptides. If one of these lines becomes visible, it means the target peptide is present in the sample. The technology can also easily be modified to detect multiple types of peptides released by different types or stages of disease.

In tests in mice, the researchers were able to accurately identify colon tumors, as well as blood clots. Bhatia says these tests represent the first step toward a diagnostic device that could someday be useful in human patients. "This is a new idea — to create an excreted biomarker instead of relying on what the body gives you," she says. "To prove this approach is really going to be a useful diagnostic, the next step is to test it in patient populations."

Reference:

Image: jasongrowclients

Homepage: http://lmrt.mit.edu/about.html

http://web.mit.edu/newsoffice/2014/a-paper-diagnostic-for-cancer-0224.html

http://timesofindia.indiatimes.com/home/science/PIO-develops-cheap-paper-test-to-detect-cancer/articleshow/30963615.cms